1122TiP A phase II trial to evaluate the safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), pheochromocytomas and paragangliomas (PPGLs)

Autor:	Gaze, M.N., O'Dorisio, M.S., Sábado, C., Brouri, F., Folitar, I.
Zdroj:	In Annals of Oncology September 2021 32 Supplement 5:S920-S920
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu